Tang Capital Management NXTC Position
ExitedTang Capital Management exited their position in NextCure, Inc. (NXTC) in Q2 2025, after holding the stock for 10 quarters.
The position was first reported in Q1 2023 and has been tracked across 10 quarterly 13F filings.
1 other tracked fund also holds NXTC.
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Full company profile →Short Interest
1.6%
1.5 days to cover
Tang Capital Management NXTC Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q2 2025 | Exited | 0 | -404,144 | $0 |
| Q1 2025 | Decreased | 404,144 | -295,856 | $194K |
| Q4 2024 | Increased | 700,000 | +47,614 | $540K |
| Q3 2024 | Increased | 652,386 | +49,392 | $894K |
| Q2 2024 | Increased | 602,994 | +458,474 | $959K |
| Q1 2024 | Decreased | 144,520 | -323,402 | $322K |
| Q4 2023 | Increased | 467,922 | +67,922 | $533K |
| Q3 2023 | Held | 400,000 | — | $516K |
| Q2 2023 | Held | 400,000 | — | $720K |
| Q1 2023 | New | 400,000 | +400,000 | $592K |
Frequently Asked Questions
Does Tang Capital Management own NXTC?
No. Tang Capital Management exited their position in NextCure, Inc. (NXTC) in Q2 2025. They previously held the stock for 10 quarters.
How many hedge funds own NXTC?
1 specialist biotech hedge fund currently holds NXTC, including OrbiMed Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy NXTC?
Tang Capital Management's position in NXTC was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's NXTC position increasing or decreasing?
Tang Capital Management completely exited their NXTC position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
NXTCCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →